stockmarketproxy
/
ABTNYSESEC EDGAREDGAR

ABBOTT LABORATORIES

Pharmaceutical Preparations·ABBOTT PARK, IL·FY end 12/31·CIK 1800
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$44.3B$42.0B$40.1B$43.7B$43.1B
Gross Profit——————
Operating Income$8.1B$6.8B$6.5B$8.4B$8.4B
Net Income$6.5B$13.4B$5.7B$6.9B$7.1B
Operating CF$9.6B$8.6B$7.3B$9.6B$10.5B
Capex$2.2B$2.2B$2.2B$1.8B$1.9B
Free Cash Flow$7.4B$6.4B$5.1B$7.8B$8.6B
Buybacks$893.0M$1.3B$1.2B$3.8B$2.3B
Dividends$4.1B$3.8B$3.6B$3.3B$3.2B
Gross Margin——————
Operating Margin18.2%16.3%16.2%19.2%19.6%
Net Margin14.7%31.9%14.3%15.9%16.4%
FCF Margin16.7%15.1%12.6%17.9%20.1%
R&D / Revenue6.6%6.8%6.8%6.6%6.4%
Effective Tax22.9%-91.1%14.1%16.5%13.9%
Debt / Equity0.440.560.730.850.99
Buybacks / FCF12.1%20.4%24.3%48.6%26.6%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
ABT
166:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
PTCT
7:1
CEO total comp
ABT
$24M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
PTCT
$23M
Net Margin
ABT
14.7%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
PTCT
39.4%